The lawsuit accuses the life sciences giant of duping Valtech Cardio Ltd. investors into deferring $350 million in compensation—out of up to $690 million—as part of a scheme to block commercialization of the “Cardioband” system while Edwards developed a competing product. The upfront sale price was $340 million, according to the complaint made public Tuesday.
“As defendants continue to sideline Cardioband for their financial benefit"—depriving former Valtech ...